How Probenecid Affects Tigecycline Levels
Probenecid inhibits the renal secretion of tigecycline by blocking organic anion transporters (OATs) in the kidneys, reducing its clearance and increasing plasma concentrations. This interaction raises tigecycline's area under the curve (AUC) by about 1.3- to 2-fold and extends its half-life from roughly 42 hours to 51-120 hours, depending on dose and patient factors.[1][2]
Clinical Evidence from Studies
In a randomized crossover study with healthy volunteers, co-administration of probenecid (500 mg twice daily) with tigecycline (100 mg IV) increased maximum concentration (Cmax) by 34-38%, AUC by 38-49%, and half-life by 25-30% compared to tigecycline alone. Urinary excretion of tigecycline dropped by over 50%, confirming reduced renal elimination as the mechanism.[1] Similar effects appear in population pharmacokinetic models for critically ill patients.[3]
Why This Interaction Occurs
Tigecycline undergoes minimal metabolism (less than 20%) and is primarily eliminated unchanged via biliary and renal routes—about 15-20% renally through active secretion. Probenecid competitively inhibits OAT1 and OAT3 transporters in proximal tubules, trapping tigecycline in the bloodstream longer. This does not significantly alter volume of distribution or protein binding.[2][4]
Dosing Adjustments and Risks
No formal dose reduction is mandated, but guidelines recommend monitoring tigecidycline levels and avoiding probenecid unless benefits outweigh risks, especially in renal impairment. Elevated tigecycline exposure heightens nausea, vomiting, and potential neurotoxicity, though severe adverse events remain rare in trials.[1][5] Use caution in patients with creatinine clearance below 30 mL/min.
When Is This Combination Used?
Rarely intentional, but probenecid might extend tigecycline's duration in multidrug-resistant infections (e.g., Acinetobacter). Alternatives like extending infusion times achieve similar exposure boosts without drug interactions.[3]
Sources
[1] PubMed: Probenecid-tigecycline interaction study
[2] FDA Tigecycline Label
[3] Antimicrobial Agents and Chemotherapy: PK modeling
[4] Clinical Pharmacokinetics Review
[5] IDSA Guidelines on Tigecycline Use